Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Jul;41(1):10-4.
doi: 10.1007/BF01788954.

Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up

W Den Otter  1 , F W Hill, W R Klein, J W Koten, P A Steerenberg, P H De Mulder, C Rhode, R Stewart, J A Faber, E J Ruitenberg, et al.
Affiliations
Clinical Trial

Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up

W Den Otter et al. Cancer Immunol Immunother. 1995 Jul.

Abstract

We have tested the therapeutic potency of peritumorally injected low doses of interleukin-2 (IL-2). Seventy tumours of the bovine ocular squamous-cell carcinoma (BOSCC), 1-3 cm in diameter, were treated with 5000, 20,000 or 200,000 U IL-2 from Eurocetus (Chiron) to find the optimal dose for treatment. Injections were given peritumorally on Monday to Friday on 2 consecutive weeks. The size of the tumours was measured before treatment and 1, 3, 4, 9 and 20 months after treatment. After 9 months complete regression was observed in 89% of the tumours treated with 5000 U IL-2, 80% treated with 20,000 U and 67% treated with 200,000 U. After 20 months, there was complete regression of 35%, 31% and 67% of the tumours respectively. The 9- and 20-month results of the 200,000-U treatment are significantly better than those of the 5000-U and 20,000-U treatments taken together. This protocol may be useful to treat advanced inoperable tumours (e.g. of the nasopharynx or skin) of human patients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bernsen M, Dullens HFJ, Den Otter W, Heintz APM. Chemoimmunotherapy with a combination of low-dose cisplatin and recombinant interleukin 2. In: Sharp F, Masen WP, Creasman W, editors. Ovarian cancer 2. Biology, diagnosis and management. London: Chapman & Hall; 1992. pp. 189–194.
    1. Cordy DR. Ocular squamous carcinoma on cattle. In: Moulton JE, editor. Tumors in domestic animals. 3rd edn. Los Angeles: University of California Press; 1991. p. 654.
    1. De Mik HJI, Koten JW, Maas RA, Dullens HFJ, Den Otter W. Tumor regression by IL-2 mediated stagnation of blood flow. In Vivo. 1991;5:679–684. - PubMed
    1. Den Otter W, Koten JW, Van der Vegt BJH, Beemer FA, Boxma OJ, DerKinderen DJ, De Graaf PW, Huber J, Lips CJM, Roholl PJM, Sluijter FJH, Tan KEWP, Van der Heyden KA, Van der Ven L, Van Unnik JA. Oncogenesis by mutations in anti-oncogenes: a view. Anticancer Res. 1990;10:475–488. - PubMed
    1. Den Otter W, Maas RA, Koten JW. Effective immunotherapy with local low doses of interleukin-2. In Vivo. 1991;5:561–566. - PubMed

Publication types

LinkOut - more resources